Here are the top headlines from Fox Business Flash. Check out what is clicking on FoxBusiness.com.
Gilead Inc. said Friday that U.S. The Food and Drug Administration extended the validity of the emergency use of its experimental antiviral COVID-19 treatment, rimadesivir, so that it could be used in all COVID-19 patients admitted to the hospital.
Get Fox Business on the go by clicking here
The drug was authorized in May for use in patients with severe forms of the disease, after trial data the antiviral drug helped shorten the hospital’s recovery time. A study published last week found that patients with more moderate CVD-19 had a modest benefit after being given the drug.
Coronavirus Relief Bill, Vaccines Must Be Finished
The study found that typically sick patients treated with antiviral medication for five days, compared to patients receiving standard treatment, improved significantly in some areas such as whether they needed supplemental oxygen. But, the significance of that benefit was uncertain, Gilead said, due to constant questions about how to best measure non-existent patient outcomes.
| Ticker | Security | The last | Change | Change% |
|---|---|---|---|---|
| Guild | Gilead Science Inc. | 65.26 | -0.29 | -0.44% |
The FDA said in a press release that it concluded that remedivisor may be effective in treating the disease and that the potential benefits outweigh the risks.
Click here to read more on Fox Business
(Reporting by Michael Irman in Maplewood, NJ and Michaelica Roy; edited by Shinjini Ganguly and Leslie Adler)
